Adenovirus-mediated interleukin-12 gene therapy for prostate cancer

Yasutomo Nasu, Shin Ebara, Hiromi Kumon

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

As a human prostate cancer gene therapy trial, we have performed Herpes Simplex Virus-thymidine kinase gene transduction and ganciclovir therapy in locally advanced prostate cancer after radiation therapy(USA) or endocrine therapy(Japan). Safety and clinical efficacy were confirmed. In our current studies, we demonstrated the efficacy and safety of gene therapy approaches using recombinant adenoviral vector that transduce interleukin-12 in an orthotopic mouse model of prostate cancer. These preclinical studies will soon be resulted in the initiation of clinical trials using this approach(USA: FDA approved, Japan: Under IRB review) in advanced prostate cancer patients with or without metastasis after endocrine therapy. In this chapter, preclinical data and clinical protocol are introduced.

Original languageEnglish
Pages (from-to)1181-1191
Number of pages11
JournalNihon rinsho. Japanese journal of clinical medicine
Volume62
Issue number6
Publication statusPublished - 2004

Fingerprint

Interleukin-12
Adenoviridae
Genetic Therapy
Prostatic Neoplasms
Japan
Safety
Ganciclovir
Thymidine Kinase
Neoplasm Genes
Research Ethics Committees
Simplexvirus
Clinical Protocols
Radiotherapy
Therapeutics
Clinical Trials
Neoplasm Metastasis
Genes

Cite this

Adenovirus-mediated interleukin-12 gene therapy for prostate cancer. / Nasu, Yasutomo; Ebara, Shin; Kumon, Hiromi.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 62, No. 6, 2004, p. 1181-1191.

Research output: Contribution to journalArticle

@article{53bd5945919645a78fa96b36b2c759d2,
title = "Adenovirus-mediated interleukin-12 gene therapy for prostate cancer",
abstract = "As a human prostate cancer gene therapy trial, we have performed Herpes Simplex Virus-thymidine kinase gene transduction and ganciclovir therapy in locally advanced prostate cancer after radiation therapy(USA) or endocrine therapy(Japan). Safety and clinical efficacy were confirmed. In our current studies, we demonstrated the efficacy and safety of gene therapy approaches using recombinant adenoviral vector that transduce interleukin-12 in an orthotopic mouse model of prostate cancer. These preclinical studies will soon be resulted in the initiation of clinical trials using this approach(USA: FDA approved, Japan: Under IRB review) in advanced prostate cancer patients with or without metastasis after endocrine therapy. In this chapter, preclinical data and clinical protocol are introduced.",
author = "Yasutomo Nasu and Shin Ebara and Hiromi Kumon",
year = "2004",
language = "English",
volume = "62",
pages = "1181--1191",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "6",

}

TY - JOUR

T1 - Adenovirus-mediated interleukin-12 gene therapy for prostate cancer

AU - Nasu, Yasutomo

AU - Ebara, Shin

AU - Kumon, Hiromi

PY - 2004

Y1 - 2004

N2 - As a human prostate cancer gene therapy trial, we have performed Herpes Simplex Virus-thymidine kinase gene transduction and ganciclovir therapy in locally advanced prostate cancer after radiation therapy(USA) or endocrine therapy(Japan). Safety and clinical efficacy were confirmed. In our current studies, we demonstrated the efficacy and safety of gene therapy approaches using recombinant adenoviral vector that transduce interleukin-12 in an orthotopic mouse model of prostate cancer. These preclinical studies will soon be resulted in the initiation of clinical trials using this approach(USA: FDA approved, Japan: Under IRB review) in advanced prostate cancer patients with or without metastasis after endocrine therapy. In this chapter, preclinical data and clinical protocol are introduced.

AB - As a human prostate cancer gene therapy trial, we have performed Herpes Simplex Virus-thymidine kinase gene transduction and ganciclovir therapy in locally advanced prostate cancer after radiation therapy(USA) or endocrine therapy(Japan). Safety and clinical efficacy were confirmed. In our current studies, we demonstrated the efficacy and safety of gene therapy approaches using recombinant adenoviral vector that transduce interleukin-12 in an orthotopic mouse model of prostate cancer. These preclinical studies will soon be resulted in the initiation of clinical trials using this approach(USA: FDA approved, Japan: Under IRB review) in advanced prostate cancer patients with or without metastasis after endocrine therapy. In this chapter, preclinical data and clinical protocol are introduced.

UR - http://www.scopus.com/inward/record.url?scp=3442892403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3442892403&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 1181

EP - 1191

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 6

ER -